LOBE Stock Overview
A biopharmaceutical company, focuses on the research and development using sub-hallucinatory doses of proprietary psychedelic compounds to improve brain and mental health, and wellness. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Lobe Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.02 |
| 52 Week High | CA$0.025 |
| 52 Week Low | CA$0.01 |
| Beta | 2.12 |
| 11 Month Change | 33.33% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | -91.67% |
| 5 Year Change | -96.49% |
| Change since IPO | -98.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| LOBE | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | 0.04% |
| 1Y | 0% | -32.7% | 22.7% |
Return vs Industry: LOBE exceeded the Canadian Pharmaceuticals industry which returned -32% over the past year.
Return vs Market: LOBE underperformed the Canadian Market which returned 23.3% over the past year.
Price Volatility
| LOBE volatility | |
|---|---|
| LOBE Average Weekly Movement | 35.5% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: LOBE's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: LOBE's weekly volatility has decreased from 41% to 35% over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Fred Sancilio | www.lobesciences.com |
Lobe Sciences Ltd., a biopharmaceutical company, focuses on the research and development using sub-hallucinatory doses of proprietary psychedelic compounds to improve brain and mental health, and wellness. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020.
Lobe Sciences Ltd. Fundamentals Summary
| LOBE fundamental statistics | |
|---|---|
| Market cap | CA$2.57m |
| Earnings (TTM) | -CA$2.97m |
| Revenue (TTM) | CA$976.74k |
3.5x
P/S Ratio-1.2x
P/E RatioIs LOBE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LOBE income statement (TTM) | |
|---|---|
| Revenue | CA$976.74k |
| Cost of Revenue | CA$25.77k |
| Gross Profit | CA$950.97k |
| Other Expenses | CA$3.92m |
| Earnings | -CA$2.97m |
Last Reported Earnings
May 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 97.36% |
| Net Profit Margin | -303.68% |
| Debt/Equity Ratio | -199.0% |
How did LOBE perform over the long term?
See historical performance and comparison